Treatment efficacy of a probiotic preparation for non‐alcoholic steatohepatitis: A pilot trial

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Journal of Digestive Diseases

• Publication date

  2017-12-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1111/1751-2980.12561PMID 29148175
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Blood Trimethylamine-N-Oxide Originates from Microbiota Mediated Breakdown of Phosphatidylcholine and Absorption from Small Intestine

  2017cited by this paper
• Current and future treatment options in non-alcoholic steatohepatitis (NASH)

  2017cited by this paper
• Genetic and epigenetic mechanisms of NASH

  2016cited by this paper
• PNPLA3 as a Genetic Determinant of Risk for and Severity of Non-alcoholic Fatty Liver Disease Spectrum

  2016cited by this paper
• Intestinal-borne dermatoses significantly improved by oral application of Escherichia coli Nissle 1917.

  2016cited by this paper
• Small Intestinal Bacterial Overgrowth Is Associated with Non-Alcoholic Fatty Liver Disease.

  2016cited by this paper
• Non-alcoholic fatty liver disease: what the clinician needs to know.

  2014cited by this paper
• Shear Wave Elastography for Evaluation of Liver Fibrosis

  2014cited by this paper
• Hepatic fibrosis: prospective comparison of MR elastography and US shear-wave elastography for evaluation.

  2014cited by this paper
• Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: A connection between endogenous alcohol and NASH

  2013cited by this paper
• Glitazones for human nonalcoholic steatohepatitis

  2011cited by this paper
• Lowering Bile Acid Pool Size with a Synthetic Farnesoid X Receptor (FXR) Agonist Induces Obesity and Diabetes through Reduced Energy Expenditure*

  2011cited by this paper
• Gut microbiota and probiotics in chronic liver diseases.

  2011cited by this paper
• NASH: A global health problem

  2011cited by this paper
• A pilot trial of high-dose ursodeoxycholic acid in nonalcoholic steatohepatitis

  2010cited by this paper
• High‐dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double‐blind, randomized, placebo‐controlled trial

  2010cited by this paper
• Yeasts in the gut: from commensals to infectious agents.

  2009cited by this paper
• Effects of light-to-moderate alcohol consumption on steatosis and steatohepatitis in severely obese patients

  2009cited by this paper

• Probiotic-Driven Competitive Exclusion in the Human Gut: A Meta-Analysis of Microbial Diversity and Pathogen Suppression

  2026cites this paper
• Therapeutic Potential of Probiotics in Metabolic Dysfunction-Associated Steatohepatitis: A Comprehensive Review

  2025cites this paper
• Future potential therapeutics to treat MASH.

  2025cites this paper
• Meta-analysis reveals Bifidobacterium as a promising therapy for non-alcoholic fatty liver disease

  2025cites this paper
• Exploring the Role of Probiotics, Prebiotics, and Synbiotics in the Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease—A Scoping Review

  2025cites this paper
• Gut Microbiota and Liver Health: Meta-Analysis of Bifidobacterium-Containing Probiotics in NAFLD Management

  2025influential citation
• Dietary Strategies to Modulate Gut Microbiota in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

  2025cites this paper
• Bacillus subtilis pb2441 Ameliorates Hepatic Steatosis by Decoupling Liver and Fat Tissue Lipid Accumulation in a High-Fat Diet-Fed Mouse Model

  2025cites this paper
• Effect of synbiotics on the cardiovascular risk factors in patients with non-alcoholic fatty liver: a GRADE assessed systematic review and meta-analysis

  2025cites this paper
• Unlocking the gut-liver axis: microbial contributions to the pathogenesis of metabolic-associated fatty liver disease

  2025cites this paper
• The Intestinal Thread of Fate: How the Microbiota Shapes the Story of Liver Disease

  2025cites this paper
• A Pathophysiology‐Informed, Negentropy‐Oriented Strategy for Nanomedicine in MASLD

  2025cites this paper
• Elucidating the effects of probiotics on metabolic dysfunction-associated steatotic liver disease: a meta-analysis

  2025influential citation
• The effect of gut microbiome-targeted therapies in nonalcoholic fatty liver disease: a systematic review and network meta-analysis

  2025cites this paper
• Chlorogenic Acid’s Role in Metabolic Health: Mechanisms and Therapeutic Potential

  2025cites this paper
• Optimal probiotic combinations for treating nonalcoholic fatty liver disease: A systematic review and network meta-analysis.

  2024cites this paper
• Effects of Probiotics on Liver Diseases: Current In Vitro and In Vivo Studies

  2024cites this paper
• The role of probiotics in the treatment of Non-Alcoholic Fatty Liver Disease (NAFLD): new insights based on meta-analysis and subgroup analysis

  2024cites this paper
• The Role of Gut Microbiota Modification in Nonalcoholic Fatty Liver Disease Treatment Strategies

  2024cites this paper
• Role of the Gut Microbiome in Metabolic Dysfunction-Associated Steatotic Liver Disease

  2024cites this paper
• Meta-analysis of randomized controlled trials of the effects of synbiotics, probiotics, or prebiotics in controlling glucose homeostasis in non-alcoholic fatty liver disease patients.

  2024cites this paper
• Protection against fibrosis by a bacterial consortium in metabolic dysfunction-associated steatohepatitis and the role of amino acid metabolism

  2024cites this paper
• The effect of synbiotics on liver enzymes, obesity indices, blood pressure, lipid profile, and inflammation in patients with non-alcoholic fatty liver: a systematic review and meta-analysis of randomized controlled trials.

  2024cites this paper
• The Role of Probiotics in Managing Metabolic-Associated Fatty Liver Disease: An Updated Review

  2024cites this paper
• Natural Products as Hepatoprotective Agents—A Comprehensive Review of Clinical Trials

  2024cites this paper
• The effect of probiotic consumption on lipid profile, glycemic index, inflammatory markers, and liver function in NAFLD patients: A systematic review and meta-analysis of randomized controlled trials.

  2024cites this paper
• The effects of probiotics supplements on metabolic indices and clinical signs in patients with diabetic retinopathy, a randomized double blind clinical trial

  2024cites this paper
• Gut microbiota in MAFLD: therapeutic and diagnostic implications

  2024cites this paper
• Probiotics—A Promising Novel Therapeutic Approach in the Management of Chronic Liver Diseases

  2024cites this paper
• The Many Faces of Metabolic Dysfunction-Associated Fatty Liver Disease Treatment: From the Mediterranean Diet to Fecal Microbiota Transplantation

  2024cites this paper
• Roles of Traditional and Next-Generation Probiotics on Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH): A Systematic Review and Network Meta-Analysis

  2024cites this paper
• Improvement of NASH and liver fibrosis through modulation of the gut-liver axis by a novel intestinal FXR agonist.

  2024cites this paper
• Can modulation of gut microbiota affect anthropometric indices in patients with non-alcoholic fatty liver disease? An umbrella meta-analysis of randomized controlled trials

  2024cites this paper
• Probiotic supplementation, hepatic fibrosis, and the microbiota profile in NASH patients: a randomized controlled trial.

  2023cites this paper
• Gut Microbiota and Bacterial Translocation in the Pathogenesis of Liver Fibrosis

  2023cites this paper
• The Crosstalk between Gut Microbiota and Bile Acids Promotes the Development of Non-Alcoholic Fatty Liver Disease

  2023cites this paper
• Role of Probiotics and Gut microbiota in Liver Diseases

  2023cites this paper
• Use of probiotics, prebiotics, and synbiotics in non‐alcoholic fatty liver disease: A systematic review and meta‐analysis

  2023cites this paper
• Effects of probiotics on non-alcoholic fatty liver disease: a review of human clinical trials

  2023cites this paper
• The Role of Choline, Soy Isoflavones, and Probiotics as Adjuvant Treatments in the Prevention and Management of NAFLD in Postmenopausal Women

  2023cites this paper
• The Gut Microbiome and Autoimmune Hepatitis: Implications for Early Diagnostic Biomarkers and Novel Therapies.

  2023cites this paper
• Probiotics, prebiotics and synbiotics in nonalcoholic fatty liver disease and alcohol-associated liver disease.

  2023cites this paper
• The gut–liver axis and gut microbiota in health and liver disease

  2023cites this paper
• Using synbiotics supplementation to treat hepatic steatosis: A comprehensive meta-analysis of randomized controlled trials

  2023cites this paper
• Effects of various interventions on non-alcoholic fatty liver disease (NAFLD): A systematic review and network meta-analysis

  2023cites this paper
• Efficacy of probiotics on nonalcoholic fatty liver disease: A meta-analysis

  2023cites this paper
• Targeting the Gut Microbiome to Treat Metabolic Dysfunction-Associated Fatty Liver Disease: Ready for Prime Time?

  2022cites this paper
• Gut Microbiome in Non-Alcoholic Fatty Liver Disease: From Mechanisms to Therapeutic Role

  2022cites this paper
• Probiotics in Critically Ill Patients: An Umbrella Review

  2022cites this paper
• Fatty liver and risk of dementia NAFLD increases a risk of stroke DPP-4 inhibitor-specific biomarkers in NAFLD LPS promotes HCC by NETs formation via TLR4 CLIF-SOFA score and sepsis

  2022cites this paper
• The Effects of Probiotic Supplementation on Opioid-Related Disorder in Patients under Methadone Maintenance Treatment Programs

  2022cites this paper
• PROBIOTIC, PREBIOTIC OR SYMBIOTIC SUPPLEMENTATION IMPACTS ON INTESTINAL MICROBIOTA IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE: A SYSTEMATIC REVIEW.

  2022influential citation
• Effects of Synbiotics, Probiotics, and Prebiotics on Liver Enzymes of Patients With Non-alcoholic Fatty Liver Disease: A Systematic Review and Network Meta-Analysis

  2022cites this paper
• Effect of Probiotics on Liver Enzymes in Patients With Non-alcoholic Fatty Liver Disease: An Umbrella of Systematic Review and Meta-Analysis

  2022cites this paper
• Effect of Probiotics Therapy on Nonalcoholic Fatty Liver Disease

  2022cites this paper
• Therapeutic mechanisms and beneficial effects of non-antidiabetic drugs in chronic liver diseases

  2022cites this paper
• The promising role of probiotics/prebiotics/synbiotics in energy metabolism biomarkers in patients with NAFLD: A systematic review and meta-analysis

  2022influential citation
• The Effects of Probiotics, Prebiotics and Synbiotics in Non-Alcoholic Fat Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH): A Systematic Review

  2022cites this paper
• Probiotics for the improvement of metabolic profiles in patients with metabolic-associated fatty liver disease: A systematic review and meta-analysis of randomized controlled trials

  2022cites this paper
• Fecal Microbiota Transplantation in NAFLD Treatment

  2022cites this paper
• Comparative analysis of preventive role of different probiotics and prebiotics against the markers of liver damage, oxidative stress markers and inflammatory markers in the non-alcoholic fatty liver disease induced rats

  2022cites this paper
• The clinical effect of probiotics on patients with non-alcoholic fatty liver disease: a meta-analysis

  2022cites this paper
• Nutritional Approach Targeting Gut Microbiota in NAFLD—To Date

  2021cites this paper
• Insights into the Impact of Microbiota in the Treatment of NAFLD/NASH and Its Potential as a Biomarker for Prognosis and Diagnosis

  2021cites this paper
• Novel approaches to intervene gut microbiota in the treatment of chronic liver diseases

  2021cites this paper
• Probiotics and Prebiotics as a Strategy for Non-Alcoholic Fatty Liver Disease, a Narrative Review

  2021influential citation
• Chlorogenic Acid and Geniposide Combination Prevents NASH in Rats Fed High-fat diet via Microbiota and TLR4-LPS Pathway

  2021cites this paper
• Accomplishment of probiotics in human health pertaining to immunoregulation and disease control.

  2021cites this paper
• Nutritional supplementation for nonalcohol-related fatty liver disease: a network meta-analysis.

  2021cites this paper
• The Effect of Probiotic Supplementation as Alternative Therapy for NAFLD: A Literature Review

  2021cites this paper
• The interplay between host cellular and gut microbial metabolism in NAFLD development and prevention

  2021cites this paper
• The impact of alteration in gut microbiome in the pathogenesis of nonalcoholic fatty liver disease.

  2021cites this paper
• The Effects of Probiotic Supplementation on Glycemic Index, Lipid Pro�les and In�ammatory Cytokines in NAFLD Patients: A Protocol for a Systematic Review and Meta-Analysis

  2021influential citation
• Minor Changes in the Composition and Function of the Gut Microbiota During a 12-Week Whole Grain Wheat or Refined Wheat Intervention Correlate with Liver Fat in Overweight and Obese Adults

  2020cites this paper
• Investigation of synbiotic treatment in non-alcoholic fatty liver disease (INSYTE study): a double-blind, randomised, placebo-controlled, phase 2 trial

  2020cites this paper
• Effects of therapeutic probiotics on modulation of microRNAs

  2020cites this paper
• Nutritional and Botanical Approaches for Nonalcoholic Fatty Liver Disease

  2020cites this paper
• The role of the gut microbiome and diet in the pathogenesis of non-alcoholic fatty liver disease

  2020cites this paper
• The Role of Gut Microbiome-Targeted Therapy in Nonalcoholic Fatty Liver Disease

  2020cites this paper
• Effect of the use of probiotics, prebiotics and symbiotics in Non-Alcoholic Fatty Liver Disease

  2020cites this paper
• Microbial Metabolites: Critical Regulators in NAFLD

  2020cites this paper
• The Gut Microbiota and its Metabolites, Novel Targets for Treating and Preventing Non-Alcoholic Fatty Liver Disease.

  2020cites this paper
• Microbiome: Emerging Concepts in Patients with Chronic Liver Disease.

  2020cites this paper
• Microbiote intestinal et stéatopathie métabolique

  2020cites this paper
• Synbiotic Alters Fecal Microbiomes, but not Liver Fat or Fibrosis, in a Randomized Trial of Patients With Non-alcoholic Fatty Liver Disease.

  2020cites this paper
• The Therapeutic Implications of the Gut Microbiome and Probiotics in Patients with NAFLD

  2019influential citation
• Impact of bacterial probiotics on obesity, diabetes and non-alcoholic fatty liver disease related variables: a systematic review and meta-analysis of randomised controlled trials

  2019cites this paper
• The promising role of probiotic and synbiotic therapy in aminotransferase levels and inflammatory markers in patients with nonalcoholic fatty liver disease – a systematic review and meta-analysis

  2019cites this paper
• Microbial Population Changes and Their Relationship with Human Health and Disease

  2019cites this paper
• Intestinally derived bacterial products stimulate development of nonalcoholic steatohepatitis

  2019cites this paper
• Systematic Review with Meta-Analysis: The Effects of Probiotics in Nonalcoholic Fatty Liver Disease

  2019influential citation
• Non-alcoholic fatty liver diseases: from role of gut microbiota to microbial-based therapies

  2019cites this paper
• Role of Probiotics in Non-alcoholic Fatty Liver Disease: Does Gut Microbiota Matter?

  2019cites this paper
• Effects of probiotics on nonalcoholic fatty liver disease: a systematic review and meta-analysis

  2019cites this paper
• Review article: can bugs be drugs? The potential of probiotics and prebiotics as treatment for non‐alcoholic fatty liver disease

  2019cites this paper
• Microbiota and nonalcoholic fatty liver disease: promising prospects for clinical interventions?

  2019cites this paper
• Efficacy of Probiotics and Synbiotics in Patients with Nonalcoholic Fatty Liver Disease: A Meta-Analysis

  2019cites this paper
• Gut microbiome-targeted therapies in nonalcoholic fatty liver disease: a systematic review, meta-analysis, and meta-regression.

  2019cites this paper
• Increasing efficacy of treatment in patients with steatohepatitis and concomitant chronic colitis

  2019cites this paper
• Epigenetic Markers and Microbiota/Metabolite-Induced Epigenetic Modifications in the Pathogenesis of Obesity, Metabolic Syndrome, Type 2 Diabetes, and Non-alcoholic Fatty Liver Disease

  2019cites this paper